Literature DB >> 25753756

Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.

Srivalli Telikepalli1, Heather E Shinogle, Prem S Thapa, Jae Hyun Kim, Meghana Deshpande, Vibha Jawa, C Russell Middaugh, Linda O Narhi, Marisa K Joubert, David B Volkin.   

Abstract

An IgG2 monoclonal antibody (mAb) solution was subjected to stirring, generating high concentrations of nanometer and subvisible particles, which were then successfully size-enriched into different size bins by low-speed centrifugation or a combination of gravitational sedimentation and fluorescence-activated cell sorting (FACS). The size-fractionated mAb particles were assessed for their ability to elicit the release of cytokines from a population of donor-derived human peripheral blood mononuclear cells (PBMC) at two phases of the immune response. Fractions enriched in nanometer-sized particles showed a lower response than those enriched in micron-sized particles in this assay. Particles of 5-10 μm in size displayed elevated cytokine release profiles compared with other size ranges. Stir-stressed mAb particles had amorphous morphology, contained protein with partially altered secondary structure, elevated surface hydrophobicity (compared with controls), and trace levels of elemental fluorine. FACS size-enriched the mAb particle samples, yet did not notably alter the overall morphology or composition of particles as measured by microflow imaging, transmission electron microscopy, and scanning electron microscopy-energy dispersive X-ray spectroscopy. The utility and limitations of FACS for size separation of mAb particles and potential of in vitro PBMC studies to rank-order the immunogenic potential of various types of mAb particles are discussed.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  IgG; immune response; immunogenicity; PBMC; in vitro; monoclonal antibody; particles; protein aggregation; proteins

Mesh:

Substances:

Year:  2015        PMID: 25753756      PMCID: PMC4448733          DOI: 10.1002/jps.24379

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  62 in total

1.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses.

Authors:  Seung-Yong Seong; Polly Matzinger
Journal:  Nat Rev Immunol       Date:  2004-06       Impact factor: 53.106

2.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

Authors:  Rafael Ponce; Leslie Abad; Lakshmi Amaravadi; Thomas Gelzleichter; Elizabeth Gore; James Green; Shalini Gupta; Danuta Herzyk; Christopher Hurst; Inge A Ivens; Thomas Kawabata; Curtis Maier; Barbara Mounho; Bonita Rup; Gopi Shankar; Holly Smith; Peter Thomas; Dan Wierda
Journal:  Regul Toxicol Pharmacol       Date:  2009-04-02       Impact factor: 3.271

3.  Size fractionation of microscopic protein aggregates using a preparative fluorescence-activated cell sorter.

Authors:  Verena Rombach-Riegraf; Cyril Allard; Eline Angevaare; Anja Matter; Bahman Ossuli; Rene Strehl; Friedrich Raulf; Markus Bluemel; Kamal Egodage; Margit Jeschke; Atanas V Koulov
Journal:  J Pharm Sci       Date:  2013-05-21       Impact factor: 3.534

4.  Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.

Authors:  Hirotaka Nishi; Roman Mathäs; Robert Fürst; Gerhard Winter
Journal:  J Pharm Sci       Date:  2013-11-11       Impact factor: 3.534

5.  Improved data visualization techniques for analyzing macromolecule structural changes.

Authors:  Jae Hyun Kim; Vidyashankara Iyer; Sangeeta B Joshi; David B Volkin; C Russell Middaugh
Journal:  Protein Sci       Date:  2012-09-17       Impact factor: 6.725

6.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models.

Authors:  Amber Haynes Fradkin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

7.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

8.  Tolerance induced by physiological levels of secreted proteins in transgenic mice expressing human insulin.

Authors:  P J Whiteley; J P Lake; R F Selden; J A Kapp
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

9.  Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis.

Authors:  T A Stewart; P G Hollingshead; S L Pitts; R Chang; L E Martin; H Oakley
Journal:  Mol Biol Med       Date:  1989-08

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  15 in total

Review 1.  Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.

Authors:  Laura I Salazar-Fontana; Dharmesh D Desai; Tarik A Khan; Renuka C Pillutla; Sandra Prior; Radha Ramakrishnan; Jennifer Schneider; Alexandra Joseph
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

2.  Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS.

Authors:  Björn Boll; Emilien Folzer; Christof Finkler; Jörg Huwyler; Hanns-Christian Mahler; Roland Schmidt; Atanas V Koulov
Journal:  Pharm Res       Date:  2015-07-21       Impact factor: 4.200

3.  Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

Authors:  E M Moussa; J Kotarek; J S Blum; E Marszal; E M Topp
Journal:  Pharm Res       Date:  2016-04-01       Impact factor: 4.200

4.  Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation.

Authors:  Linda O Narhi; Quanzhou Luo; Jette Wypych; Riccardo Torosantucci; Andrea Hawe; Kiyoshi Fujimori; Yasser Nashed-Samuel; Vibha Jawa; Marisa K Joubert; Wim Jiskoot
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

5.  Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.

Authors:  Yann Gallais; Natacha Szely; François-Xavier Legrand; Arnaud Leroy; Marc Pallardy; Isabelle Turbica
Journal:  Immunol Cell Biol       Date:  2016-10-07       Impact factor: 5.126

Review 6.  Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Authors:  Wim Jiskoot; Grzegorz Kijanka; Theodore W Randolph; John F Carpenter; Atanas V Koulov; Hanns-Christian Mahler; Marisa K Joubert; Vibha Jawa; Linda O Narhi
Journal:  J Pharm Sci       Date:  2016-04-01       Impact factor: 3.534

Review 7.  Why the Immune System Should Be Concerned by Nanomaterials?

Authors:  Marc J Pallardy; Isabelle Turbica; Armelle Biola-Vidamment
Journal:  Front Immunol       Date:  2017-05-15       Impact factor: 7.561

8.  Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics.

Authors:  Marisa K Joubert; Meghana Deshpande; Jane Yang; Helen Reynolds; Christine Bryson; Mark Fogg; Matthew P Baker; Jonathan Herskovitz; Theresa J Goletz; Lei Zhou; Michael Moxness; Gregory C Flynn; Linda O Narhi; Vibha Jawa
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

9.  Editor's Highlight: Subvisible Aggregates of Immunogenic Proteins Promote a Th1-Type Response.

Authors:  Kirsty D Ratanji; Rebecca J Dearman; Ian Kimber; Robin Thorpe; Meenu Wadhwa; Jeremy P Derrick
Journal:  Toxicol Sci       Date:  2016-06-30       Impact factor: 4.849

10.  T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.

Authors:  Vibha Jawa; Frances Terry; Jochem Gokemeijer; Shibani Mitra-Kaushik; Brian J Roberts; Sophie Tourdot; Anne S De Groot
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.